Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
7,617 results
- Augmenting Buried in Treasures Workshop (BIT) With In-home Decluttering Practice for Individuals With Hoarding Disorder: Complete Statistical AnalysisIndependent statistical analysis of Augmenting Buried in Treasures Workshop (BIT) With In-home Decluttering Practice for Individuals With Hoarding Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Augmenting Effects of L-DOPS With Carbidopa and Entacapone: Complete Statistical AnalysisIndependent statistical analysis of Augmenting Effects of L-DOPS With Carbidopa and Entacapone: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00547911).
- Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- AUR0613Independent statistical analysis of Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- AURIEL-PsOIndependent statistical analysis of MSB11022 in Moderate to Severe Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02660580).
- AURIONIndependent statistical analysis of Aurinia Early Urinary Protein Reduction Predicts Response: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02949973).
- Auto Continuous Positive Airway Pressure (CPAP) Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS): Complete Statistical AnalysisIndependent statistical analysis of Auto Continuous Positive Airway Pressure (CPAP) Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS): primary endpoint results, effect estimate with confidence…
- Autologous and Allogeneic Transplant for Relapsed Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Autologous and Allogeneic Transplant for Relapsed Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00802113).
- Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene: Complete Statistical AnalysisIndependent statistical analysis of Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene: primary endpoint results, effect estimate…
- Autologous Cell Therapy for Treatment of Fecal Incontinence: Complete Statistical AnalysisIndependent statistical analysis of Autologous Cell Therapy for Treatment of Fecal Incontinence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01600755).
- Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin’s Lymphoma (BMT CTN 0202): Complete Statistical AnalysisIndependent statistical analysis of Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Autologous Polyclonal Tregs for Lupus: Complete Statistical AnalysisIndependent statistical analysis of Autologous Polyclonal Tregs for Lupus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02428309).
- Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Autologous Stem Cell Treatment for Chronic Lung Disease Study: Complete Statistical AnalysisIndependent statistical analysis of Autologous Stem Cell Treatment for Chronic Lung Disease Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03044431).
- Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009): Complete Statistical AnalysisIndependent statistical analysis of Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer…
- Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma: primary endpoint results, effect estimate with confidence interval,…
- Automated Mobile Contingency Management for Smoking Cessation: A Pilot RCT (SCC PREVAILgo): Complete Statistical AnalysisIndependent statistical analysis of Automated Mobile Contingency Management for Smoking Cessation: A Pilot RCT (SCC PREVAILgo): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Automatic Periodic Stimulation and Continuous Electromyography (EMG) for Facial Nerve Monitoring During Parotidectomy: Complete Statistical AnalysisIndependent statistical analysis of Automatic Periodic Stimulation and Continuous Electromyography (EMG) for Facial Nerve Monitoring During Parotidectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- AutonomyIndependent statistical analysis of A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04619420).
- AVAIIndependent statistical analysis of AVAI: Atrial Ventricular Arrythmia Incidence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00832975).
- AVALLIndependent statistical analysis of Assessment of an School-based Intervention in Eating Habits and Physical Activity in Schoolchildren: the AVall Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- AvatarHELPIndependent statistical analysis of Care.Coach Avatars for Improvement of Outcomes in Hospitalized Elders, Including Mitigation of Falls and Delirium: a Multi-Site Clinical Study: primary endpoint results, effect estimate with confidence interval, sample-size…
- Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure: Complete Statistical AnalysisIndependent statistical analysis of Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Avelumab in First-line NSCLC (JAVELIN Lung 100): Complete Statistical AnalysisIndependent statistical analysis of Avelumab in First-line NSCLC (JAVELIN Lung 100): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02576574).
- Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100): Complete Statistical AnalysisIndependent statistical analysis of Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300): Complete Statistical AnalysisIndependent statistical analysis of Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02625623).
- Avenir Müller Hip Stem Post Market Surveillance Study: Complete Statistical AnalysisIndependent statistical analysis of Avenir Müller Hip Stem Post Market Surveillance Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04079127).
- AVERROESIndependent statistical analysis of A Phase III Study of Apixaban in Patients With Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia: Complete Statistical AnalysisIndependent statistical analysis of Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04652479).
- Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02698891).
- AVR_HEORIndependent statistical analysis of EaseVRx-8w+ for the Treatment of Chronic Lower Back Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05263037).
- AWARD-2Independent statistical analysis of A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01075282).
- AWARD-6Independent statistical analysis of the randomized phase 3 AWARD-6 trial comparing dulaglutide with liraglutide in type 2 diabetes, including the HbA1c non-inferiority analysis, secondary endpoints, statistical methods, safety, and interpretation.
- AWARD-CHN3Independent statistical analysis of A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- AWARD-JPNIndependent statistical analysis of A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- AWARD-PEDSIndependent statistical analysis of A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- AwareIndependent statistical analysis of HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania: Complete Statistical AnalysisIndependent statistical analysis of Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01654523).
- AXEBEAMIndependent statistical analysis of Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- AXELIndependent statistical analysis of An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00920816).
- Azacitidine and CAPOX in Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine and CAPOX in Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01193517).
- Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Azacitidine and Pembrolizumab in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine and Pembrolizumab in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03264404).
- Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: primary endpoint…
- AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02513563).
- AZI001Independent statistical analysis of Azithromycin in Bronchiolitis Obliterans Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01009619).